Treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Customize your policy alerts
Sign up for Bluecross Idaho Policy 5.01.667 alerts
Get alerted when Policy 5.01.667 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity and prior authorization for intravenous or subcutaneous immunoglobulin therapy and Vyvgart Hytrulo for individuals with chronic inflammatory demyelinating polyneuropathy. Coverage depends on diagnosis, objective impairment, treatment response, documentation, and product-specific requirements.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.